Interferon‐lambda genotype and low serum low‐density lipoprotein cholesterol levels in patients with chronic hepatitis C infection

Recently, genetic polymorphisms occurring in the interferon (IFN)‐lambda gene region were associated with response to IFN‐based treatment of hepatitis C infection. Both infection with the hepatitis C virus and IFN therapy are associated with decreased serum cholesterol and high cholesterol has been...

Full description

Saved in:
Bibliographic Details
Published inHepatology (Baltimore, Md.) Vol. 51; no. 6; pp. 1904 - 1911
Main Authors Li, Josephine H., Qian Lao, Xiang, Tillmann, Hans L., Rowell, Jennifer, Patel, Keyur, Thompson, Alexander, Suchindran, Sunil, Muir, Andrew J., Guyton, John R., Gardner, Stephen D., McHutchison, John G., McCarthy, Jeanette J.
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.06.2010
Wiley
Wolters Kluwer Health, Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Recently, genetic polymorphisms occurring in the interferon (IFN)‐lambda gene region were associated with response to IFN‐based treatment of hepatitis C infection. Both infection with the hepatitis C virus and IFN therapy are associated with decreased serum cholesterol and high cholesterol has been associated with increased likelihood to respond to IFN. We sought to determine if the IFN‐lambda gene variant was also associated with serum lipid levels in chronic hepatitis C patients. We compared genotypes of the rs12979860 polymorphism, located proximal to the IL28 gene, with serum lipid and apolipoprotein levels in 746 subjects with chronic hepatitis C virus infection, not currently undergoing treatment, using multivariable analysis of variance. Levels of total cholesterol (P = 6.0 × 10−4), apolipoprotein B (P = 1.3 × 10−6) and low‐density lipoprotein (LDL) cholesterol (P = 8.9 × 10−10) were significantly higher in subjects carrying the rs12979860 CC responder genotype compared with those with the CT or TT genotype. Levels of triglycerides (P = 0.03), apolipoprotein A‐I (P = 0.06), and apolipoprotein E (P = 0.01) were slightly lower in the rs12979860 CC genotype group, whereas levels of high‐density lipoprotein cholesterol (P = 0.78) and apolipoprotein C‐III (P = 0.74) did not vary by rs12979860 genotype. Conclusion: Our results suggest that low levels of LDL cholesterol in chronic hepatitis C patients may be a marker of host endogenous IFN response to hepatitis C and that subjects with the rs12979860 CC responder genotype may have a lower endogenous IFN response to the virus. HEPATOLOGY 2010
Bibliography:fax: 919‐613‐6448
Potential conflict of interest: Study collaborators Arlene Hughes and Michael Mosteller and co‐author Stephen Gardner are employed by GlaxoSmithKline. Dr. Thompson is a consultant for Schering‐Plough. Dr. McHutchison received grants from Echosers, Idera Pharmaceutical, Intarcia, Medtronic, Osiris Therapeutics, Three Rivers Pharmaceuticals, and ViroChem Pharma. He is a consultant for and received grants from Abbott Laboratories, Biolex, Gilead, GlaxoSmithKline, GlobeImmune, Hoffman‐LaRoche, Human Genome Sciences, Intarcia, Merck Group, Novartis, Pfizer, Pharmasset, and Vertex. He is also a consultant for Anadys, Avila, Epiphany Biosciences, and iTheRx.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0270-9139
1527-3350
1527-3350
DOI:10.1002/hep.23592